SCHEMBL7164367

SCHEMBL7164367

COc1ccccc1CNCc1cccc2c1C(S(=O)(=O)c1ccccc1)CS2(=O)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.42
KMT2A Q03164 5/20 0.42
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 4/20 0.41
MEN1 O00255 4/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
PKM P14618 1/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GAA P10253 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HSD17B10 Q99714 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
POLB P06746 1/20 0.39
HTT P42858 1/20 0.39
GRIN1 Q05586 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7160223 0.99 RAB9A (0.41) RAB9AKMT2AKDM4EALDH1A1MEN1
SCHEMBL7132354 0.93 KMT2A (0.46) KMT2AKDM4EALDH1A1MEN1CYP1A2
SCHEMBL7126147 0.91 APLNR (0.47) RAB9AKMT2AKDM4EALDH1A1MEN1
SCHEMBL7164364 0.89 RAB9A (0.43) RAB9AKMT2AKDM4EALDH1A1MEN1
SCHEMBL7133168 0.88 KDM4E (0.49) KMT2AKDM4EALDH1A1MEN1GAA
SCHEMBL7129579 0.88 SMN1; SMN2 (0.43) RAB9AKMT2AKDM4EALDH1A1MEN1
Hydrochloric Acid SCHEMBL7160227 0.88 RAB9A (0.43) RAB9AKMT2AKDM4EALDH1A1MEN1
SCHEMBL7693053 0.86 KMT2A (0.46) KMT2AKDM4EALDH1A1MEN1PKM
SCHEMBL7133441 0.86 KMT2A (0.44) KMT2AKDM4EALDH1A1MEN1PKM
SCHEMBL7132604 0.86 CA1 (0.37) ALDH1A1PKMSMN1; SMN2GAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO RAB9A 4644/4885KMT2A 3177/4885KDM4E 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.